The effect of CYP1A2 gene polymorphisms on Theophylline metabolism and chronic obstructive pulmonary disease in Turkish patients

• Published in: BMB reports Vol. 43; no. 8; pp. 530 - 534
• Main Authors: Uslu, Ahmet, Medical Park Hospital, Winston-Salem, North Carolina, USA, Ogus, Candan, Akdeniz University, Antalya, Turkey, Ozdemir, Tulay, Akdeniz University, Antalya, Turkey, Bilgen, Turker, Akdeniz University, Antalya, Turkey, Tosun, Ozgur, Akdeniz University, Antalya, Turkey, Keser, Ibrahim, Akdeniz University, Antalya, Turkey
• Format: Journal Article
• Language: English
• Published: Korea (South) 생화학분자생물학회 01.08.2010
• Subjects: Aged; Alleles; Bronchodilator Agents - blood; Bronchodilator Agents - therapeutic use; Cytochrome P-450 CYP1A2 - genetics; Cytochrome P-450 CYP1A2 - metabolism; European Continental Ancestry Group - genetics; Female; Gene Frequency; Humans; Male; Middle Aged; POLIMORFISMO; POLYMORPHISM; Polymorphism, Genetic; POLYMORPHISME; Pulmonary Disease, Chronic Obstructive - blood; Pulmonary Disease, Chronic Obstructive - drug therapy; Pulmonary Disease, Chronic Obstructive - genetics; TEOFILINA; THEOPHYLLINE; Theophylline - blood; Theophylline - therapeutic use; Turkey; Turkish population; 화학; Turkey
• ISSN: 1976-6696; 1976-670X
• DOI: 10.5483/bmbrep.2010.43.8.530

Cytochrome P450 (CYP) 1A2 gene polymorphisms are thought to be involved in the metabolism of theophylline (TP). We aimed to investigate the effect of CYP1A2*1C, CYP1A2*1D, CYP1A2*1E, and CYP1A2*1F polymorphisms of the CYP1A2 on TP metabolism by PCR-RFLP in 100 Turkish patients with chronic obstructive pulmonary disease (COPD) receiving TP. One hundred and one healthy volunteers were included as control group. The genotype frequencies of the CYP1A2*1D and CYP1A2*1F were found to be significantly different in the patients compared to the controls. The "T" allele at -2467 delT and the "C" allele at -163 C greater than A in the CYP1A2 displayed association with a significantly increased risk for COPD. "T" allele at -2467 delT was also associated with a high risk of disease severity in COPD. In conclusion, our data suggest that genetic alterations in CYP1A2 may play a role both in the pharmacogenetics of TP and in the development of COPD.